×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Next Generation Sequencing Market Size

ID: MRFR/HC/4893-HCR
200 Pages
Rahul Gotadki
February 2026

Next Generation Sequencing Market Research Report: Size, Share, Trend Analysis By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Other Technologies), By Product Type (Reagents, Instruments, Software, Services), By Applications (Diagnostics, Research, Personalized Medicine, Agrigenomics), By End Use (Academic Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals and Clinics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Next Generation Sequencing Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Next Generation Sequencing Size

Next Generation Sequencing Market Growth Projections and Opportunities

The market for next-generation sequencing (NGS) is significantly impacted by the growing emphasis on genomic research and the ongoing advancements in sequencing technologies. As analysts and healthcare professionals delve deeper into the intricacies of the human genome, the demand for efficient and high-throughput sequencing solutions propels market expansion and shapes the landscape of genomics research. The market is driven by the increasing applications of NGS in precision medicine and clinical diagnostics. The ability of NGS to identify genetic variants, identify disease markers, and direct personalized treatment regimens necessitates its integration into healthcare operations, shaping consumer preferences for precise healthcare arrangements. The growing prevalence of rare diseases and genetic disorders fuels interest in NGS advancements. Experts and medical services professionals use NGS to identify underlying genetic abnormalities, understand disease components, and promote specific treatments, influencing market factors in rare disease diagnosis and treatment. The market for population genomics and large-scale genomic investigations is affected by the flood. The acceptance of NGS stages for a wide range is driven by research efforts aimed at understanding population-wide genetic variations, heritability, and defenselessness to illnesses, shaping commercial trends in population-based genomics. One of the most important market factors is coordinating NGS with state-of-the-art bioinformatics and information examination tools. The demand for strong bioinformatics arrangements increases with the amount of genomic data available, which influences business sector preferences for NGS stages with integrated information investigation capabilities. Global differences in the foundation of medical care have an impact on the accessibility and adoption of NGS innovations. Disparities in research skills, aptitude, and asset availability influence the market's entry into different regions and healthcare environments. The layout of genomic services is impacted by the growth of telemedicine and remote genomic meetings. Market preferences are shaped by remote medical care administrations, which contribute to increased access to genetic mastery, especially for patients in underserved or remote areas. Increased public awareness and ethical reflection on genetics research affect market growth. Efforts to educate the public on the implications of genetic testing, privacy issues, and the ethical use of genetic data contribute to the advancement of capable genomic practices.

Next Generation Sequencing Market Size Graph
Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Next Generation Sequencing Market by 2035?

<p>The Next Generation Sequencing Market is projected to reach a valuation of 48.81 USD Billion by 2035.</p>

What was the market valuation of the Next Generation Sequencing Market in 2024?

<p>In 2024, the market valuation of the Next Generation Sequencing Market was 14.68 USD Billion.</p>

What is the expected CAGR for the Next Generation Sequencing Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Next Generation Sequencing Market during the forecast period 2025 - 2035 is 11.54%.</p>

Which technology segment is anticipated to dominate the Next Generation Sequencing Market?

<p>The Sequencing by Synthesis technology segment is anticipated to dominate, with a projected valuation of 19.12 USD Billion by 2035.</p>

What are the key product types in the Next Generation Sequencing Market?

<p>Key product types include Reagents, Instruments, Software, and Services, with Instruments projected to reach 16.0 USD Billion by 2035.</p>

How does the application of personalized medicine impact the Next Generation Sequencing Market?

<p>The application of personalized medicine is expected to grow significantly, reaching a valuation of 12.0 USD Billion by 2035.</p>

Which end-use segment is likely to contribute the most to the Next Generation Sequencing Market?

<p>Hospitals and Clinics are likely to contribute the most, with a projected valuation of 16.31 USD Billion by 2035.</p>

Who are the leading companies in the Next Generation Sequencing Market?

<p>Leading companies in the market include Illumina, Thermo Fisher Scientific, and Pacific Biosciences, among others.</p>

What is the projected growth of the Ion Semiconductor Sequencing segment by 2035?

<p>The Ion Semiconductor Sequencing segment is projected to grow to 11.73 USD Billion by 2035.</p>

How does the market for Next Generation Sequencing compare across different end-use segments?

<p>The market for Next Generation Sequencing varies, with Pharmaceutical Companies expected to reach 14.0 USD Billion by 2035, indicating diverse growth across segments.</p>

Market Summary

According to MRFR analysis, the Next Generation Sequencing Market Size was valued at USD 14.68 Billion in 2024. The market is projected to grow from USD 16.37 Billion in 2025 to USD 48.81 Billion by 2035, registering a CAGR of 11.54% during the forecast period (2025–2035). North America led the market with over 44.96% share, generating around USD 6.6 billion in revenue.
 
The Next Generation Sequencing Market is expanding rapidly due to increasing demand for genomic research and precision medicine. Key trends include declining sequencing costs, advancements in high-throughput sequencing technologies, and growing applications in cancer diagnostics, genetic disorder detection, and personalized medicine, driving adoption across research and clinical settings.

Key Market Trends & Highlights

The Next Generation Sequencing Market is poised for substantial growth driven by technological advancements and increasing applications.

  • North America remains the largest market for Next Generation Sequencing Market, reflecting robust investment in research and development. Asia-Pacific is emerging as the fastest-growing region, fueled by increasing healthcare expenditure and technological adoption. Sequencing by Synthesis continues to dominate the market, while Ion Semiconductor Sequencing is rapidly gaining traction due to its efficiency. Key market drivers include rising demand for personalized medicine and government initiatives supporting advancements in sequencing technologies.

Market Size & Forecast

2024 Market Size 14.68 (USD Billion)
2035 Market Size 48.81 (USD Billion)
CAGR (2025 - 2035) 11.54%
Largest Regional Market Share in 2024 North America

Major Players

Companies such as Illumina (US), <a href="https://www.thermofisher.com/in/en/home/life-science/sequencing/next-generation-sequencing.html" target="_blank" rel="noopener">Thermo Fisher Scientific </a>(US), Pacific Biosciences (US), Oxford Nanopore Technologies (GB), BGI Genomics (CN), Qiagen (DE), <a href="https://sequencing.roche.com/global/en/article-listing/next-generation-sequencing.html">Roche </a>(CH), Agilent Technologies (US), Genomatix (DE) are some of the major participants in the global market.

Market Trends

NGS report suggests that the Next Generation Sequencing Market is currently experiencing a transformative phase, driven by advancements in technology and increasing applications across various fields. This market encompasses a range of sequencing technologies that allow for rapid and cost-effective analysis of genetic material. As research institutions and healthcare providers increasingly adopt these innovative solutions, the demand for high-throughput sequencing is on the rise.

Technological advancements have significantly reduced sequencing costs, with the price of sequencing a human genome dropping from nearly USD 100 million in 2001 to under USD 1,000 today according to the National Human Genome Research Institute, accelerating the adoption of NGS technologies in research and clinical settings.

Furthermore, the integration of healthcare artificial intelligence and machine learning into sequencing processes is enhancing data analysis capabilities, thereby improving the accuracy and efficiency of genomic studies and upholding the growth prospects for the NGS data analysis market.

In addition to technological advancements, the Next Generation Sequencing Market is influenced by a growing emphasis on personalized medicine. Healthcare professionals are increasingly utilizing genomic data to tailor treatments to individual patients, which is likely to enhance patient outcomes. Moreover, the expansion of applications in oncology, infectious diseases, and rare genetic disorders is propelling market growth. As the landscape continues to evolve, stakeholders must remain vigilant to emerging trends and potential challenges that may arise in this dynamic environment.

Technological Advancements

The Next Generation Sequencing Market is witnessing rapid technological innovations that enhance sequencing speed and accuracy. New next gen sequencing platforms are emerging, offering improved data output and reduced next gen sequencing costs, which may attract a broader range of users, including smaller laboratories and research institutions.

Personalized Medicine

NGS report suggests that there is a notable shift towards personalized medicine within the Next Generation Sequencing Market. Healthcare providers are increasingly leveraging genomic information to develop tailored treatment plans, which could lead to better patient outcomes and a more efficient healthcare system.

Precision medicine initiatives are expanding globally, with over 60% of oncology clinical trials now incorporating genomic sequencing for biomarker identification and targeted therapy selection, driving demand for advanced NGS platforms.

Expansion of Applications

The applications of next generation sequencing are broadening significantly. Beyond traditional uses in genomics, there is a growing interest in areas such as oncology, infectious disease diagnostics, and agricultural biotechnology, indicating a diverse and expanding next generation sequencing ngs market.

The use of NGS continues to broaden, with more than 90% of rare diseases estimated to have a genetic component according to the World Health Organization, supporting the increasing application of sequencing technologies in rare disease diagnosis and genetic research.

Next Generation Sequencing Market Market Drivers

Government Initiatives and Funding

The Next Generation Sequencing Market is bolstered by various government initiatives and funding programs aimed at advancing genomic research. Governments are increasingly recognizing the importance of genomics in healthcare and are investing in initiatives that promote the development and application of sequencing technologies.
 
For example, funding for large-scale genomic projects and biobanks is becoming more prevalent, facilitating access to genomic data for research purposes. This financial support is likely to accelerate innovation within the next generation sequencing market, as it enables researchers to explore new applications and improve existing technologies. Additionally, public-private partnerships are emerging, further enhancing the collaborative environment necessary for advancing sequencing capabilities. As these initiatives continue to grow, they are expected to play a crucial role in shaping the future landscape of the next generation sequencing market.

Rising Demand for Personalized Medicine

The Next Generation Sequencing Market is significantly influenced by the increasing demand for personalized medicine. As healthcare shifts towards tailored treatment approaches, the ability to sequence an individual's genome becomes paramount. This trend is evident in oncology, where genomic profiling is utilized to identify specific mutations and inform targeted therapies.
 
The market for personalized medicine is projected to reach substantial figures, with estimates suggesting it could exceed several billion dollars by the end of the decade. This growing emphasis on individualized treatment plans is likely to drive the adoption of next generation sequencing technologies, as they provide critical insights into genetic variations that influence patient responses to therapies. Consequently, the integration of sequencing into clinical practice is expected to enhance patient outcomes and optimize healthcare resources.

Increasing Prevalence of Genetic Disorders

The Next Generation Sequencing Market is significantly impacted by the increasing prevalence of genetic disorders worldwide. As the understanding of genetic conditions expands, there is a growing need for effective diagnostic tools that can identify these disorders at an early stage. Next generation sequencing technologies offer a comprehensive approach to genetic testing, allowing for the detection of multiple genetic mutations simultaneously.
 
This capability is particularly valuable in the context of rare diseases, where traditional diagnostic methods may fall short. The market is projected to see substantial growth as healthcare providers increasingly adopt sequencing technologies to enhance diagnostic accuracy and improve patient management. Furthermore, the rising awareness of genetic testing among patients is likely to drive demand, positioning next generation sequencing as a vital component in the landscape of modern healthcare.

Technological Advancements in Sequencing Technologies

The Next Generation Sequencing Market is experiencing rapid technological advancements that enhance sequencing capabilities. Innovations such as improved sequencing platforms and bioinformatics tools are driving efficiency and accuracy. For instance, the introduction of single-cell sequencing technologies allows for the analysis of individual cells, providing insights into cellular heterogeneity.
 
This advancement is expected to propel the market, with projections indicating a compound annual growth rate of over 20% in the coming years. Furthermore, advancements in data analysis software are streamlining the interpretation of complex genomic data, making it more accessible to researchers and clinicians alike. As these technologies evolve, they are likely to expand the applications of next generation sequencing, thereby increasing its adoption across various sectors.

Expansion of Applications in Research and Clinical Settings

The Next Generation Sequencing Market is witnessing an expansion of applications across both research and clinical settings. In research, next generation sequencing is being utilized for various purposes, including genomics, transcriptomics, and epigenomics, thereby broadening its utility. Clinical applications are also on the rise, particularly in areas such as infectious disease diagnostics and genetic disorder screening.
 
The market is projected to grow as more healthcare institutions adopt sequencing technologies for routine diagnostics. Reports indicate that the clinical segment could account for a significant share of the market, driven by the need for rapid and accurate diagnostic tools. This expansion not only enhances the capabilities of healthcare providers but also fosters collaboration between academic institutions and industry, further propelling the growth of the next generation sequencing market.

Market Segment Insights

By Technology: Sequencing by Synthesis (Largest) vs. Ion Semiconductor Sequencing (Fastest-Growing)

The technology segment exhibits a diverse array of methodologies, each contributing uniquely to market dynamics. Sequencing by Synthesis holds the largest Next Generation Sequencing Market share, leveraging its robust capabilities in generating accurate and reproducible results. In contrast, Ion Semiconductor Sequencing, with rapid processing times and cost-efficiency, is emerging as a competitor, attracting significant interest from research institutions and laboratories looking for quick turnaround times.

Technology: Sequencing by Synthesis (Dominant) vs. Ion Semiconductor Sequencing (Emerging)

Sequencing by Synthesis continues to dominate the technology segment due to its established protocols and reliability in high-throughput sequencing applications. Laboratories favor this technology for comprehensive genomic studies and <a href="https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770" target="_blank" title="clinical diagnostic">clinical diagnostics</a>, benefiting from its extensive support and validation history. On the other hand, Ion Semiconductor Sequencing is rapidly gaining traction, particularly in applications requiring rapid results at lower costs. This technology leverages semiconductor technology to provide sequencing results in real-time, appealing to researchers aimed at optimizing workflows, thereby addressing the rising demand for efficient and flexible sequencing solutions.

By Product Type: Reagents (Largest) vs. Instruments (Fastest-Growing)

The product type segment is characterized by notable distribution among the key players: Reagents, Instruments, Software, and Services. Reagents hold the largest Next Generation Sequencing Market share, primarily due to their crucial role in various sequencing applications, which include library preparation and sample tracking. Following closely are next generation sequencing instruments, which have shown significant adoption rates in laboratories, leading to their growing market presence. Software and Services also play essential roles, but their share is comparatively smaller, focusing on data analysis and sequencing support.

Reagents (Dominant) vs. Instruments (Emerging)

Reagents are the backbone of the Next Generation Sequencing Market, providing essential materials that facilitate the sequencing process. These products include enzymes, buffers, and other biochemical components critical for successful sequencing operations. Their dominance is attributed to the increasing demand for precision and efficiency in <a title="genetic testing" href="https://www.marketresearchfuture.com/reports/genetic-testing-market-2009" target="_blank" rel="noopener">genetic testing</a> and research. On the other hand, Instruments represent the fastest-growing segment, driving innovation with advanced technologies that enhance throughput and scalability. Their emergence in the market is supported by the rising need for high-throughput sequencing solutions in clinical diagnostics and research applications, making them a key focus area for manufacturers.

By Application: Diagnostics (Largest) vs. Research (Fastest-Growing)

The Next Generation Sequencing Market (NGS) market is increasingly segmented by application, with diagnostics occupying the largest share. This dominance can be attributed to the rising demand for precision diagnostics in detecting genetic variations and mutations associated with diseases. Research applications follow, supported by robust funding for genomics studies and a growing need for sequencing on a larger scale. Personalized medicine and agrigenomics further contribute to the market landscape, reflecting changing healthcare models and agricultural advancements, respectively. Growth trends in this segment show a shift toward personalized medicine, propelled by innovations in genomics that facilitate tailored treatment strategies. The demand for efficient diagnostics is being fueled by advancements in technology and increasing awareness of genetic testing. Agrigenomics is emerging as a critical area, driven by the need for sustainable agricultural practices and improved crop yields. As research efforts expand, the NGS market is poised for significant evolution, marked by increased collaboration across sectors.

Diagnostics (Dominant) vs. Personalized Medicine (Emerging)

The diagnostics segment remains dominant within the Next Generation Sequencing Market due to its crucial role in disease identification and management. It benefits from ongoing advancements in technology that enhance accuracy and speed in detecting genetic disorders. Diagnostics applications are widely adopted in clinical settings, solidifying their market presence. Meanwhile, personalized medicine is recognized as an emerging segment, characterized by its potential to revolutionize patient care through customized treatment plans based on genetic information. This approach is gaining traction as healthcare shifts towards a more individualized model, emphasizing patient-specific therapies and outcomes. The interplay between these segments is critical, as advancements in diagnostics directly influence the growth and applicability of personalized medical solutions.

By End Use: Academic Institutes (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

End use segment reveals that academic institutes hold a substantial share, driven by the increasing demand for genomic research and personalized medicine studies. These institutions leverage NGS technologies for various applications, including disease research, genetic diversity studies, and biotechnology advancements. On the other hand, pharmaceutical companies are rapidly increasing their investment in NGS solutions. Their focus on drug discovery and development fuels Next Generation Sequencing Market growth as they rely on NGS for biomarker identification, <a href="https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077" target="_blank" title="companion diagnostic">companion diagnostics</a>, and <a title="precision medicine" href="https://www.marketresearchfuture.com/reports/precision-medicine-market-925" target="_blank" rel="noopener">precision medicine</a> research. Growth trends in the NGS end-use segment are largely propelled by technological advancements and the decreasing costs of sequencing. Academic institutes continue to adopt NGS for research initiatives, while pharmaceutical companies are prioritized in developing therapeutics, enhancing their reliance on precise genomic data to streamline drug development processes. The rising prevalence of genetic disorders and the need for innovative treatment solutions further amplify the growth potential for both segments within the NGS market.

Academic Institutes (Dominant) vs. Pharmaceutical Companies (Emerging)

Academic institutes are the dominant players in the Next Generation Sequencing Market, harnessing NGS technologies primarily for groundbreaking research in genomics, cancer studies, and personalized medicine. Their initiatives are foundational, often resulting in pivotal discoveries that fuel further industry developments. Conversely, pharmaceutical companies represent an emerging segment characterized by their swift adoption of NGS for drug discovery and development processes. They utilize NGS for precision medicine, identifying genetic biomarkers that are crucial for companion diagnostics. While academic institutes rely heavily on federal funding and collaborations, pharmaceutical firms engage in strategic partnerships and investments to bolster their R&amp;D capabilities, ultimately positioning themselves to leverage the evolving landscape of genomic medicine.

Get more detailed insights about Next Generation Sequencing Market Research Report - Forecast till 2035

Regional Insights

North America : Innovation and Leadership Hub

North America leads in the Next Generation Sequencing Market Size, accounting for over 44.96% of the global revenue in 2024. The region benefits from robust funding for research and development, a strong presence of biotechnology firms, and favorable regulatory frameworks. The increasing demand for personalized medicine and advancements in genomics are key growth drivers, alongside government initiatives supporting genomic research.

The United States leads the NGS market, with major players like Illumina, Thermo Fisher Scientific, and Pacific Biosciences headquartered there. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players. Canada is also emerging as a significant contributor, focusing on genomics research and healthcare applications, further enhancing the region's market position.

Europe : Regulatory Support and Growth

Europe Next Generation Sequencing Market size was valued at USD 4.40 Billion in 2024, making it the second-largest regional market with a 30% share. The region is witnessing significant growth driven by increasing investments in genomics research, advancements in healthcare technologies, and supportive regulatory frameworks. The European Union's initiatives to promote genomic research and personalized medicine are pivotal in shaping the market landscape.

Leading countries in Europe include Germany, the United Kingdom, and France, which are home to several key players like Qiagen and Roche. The competitive landscape is marked by collaborations between academic institutions and industry leaders, fostering innovation. The presence of regulatory bodies ensures compliance and quality standards, further enhancing market growth. The European Medicines Agency emphasizes the importance of genomics in drug development, highlighting the region's commitment to advancing NGS technologies.

Asia-Pacific : Emerging Market Potential

Asia-Pacific is rapidly emerging as a significant player in the Next Generation Sequencing Market, holding approximately 20% of the global market share. The region's growth is fueled by increasing investments in healthcare infrastructure, rising awareness of genomics, and government initiatives promoting biotechnology. Countries like China and India are leading the charge, with substantial funding directed towards genomic research and applications in healthcare.

China is the largest market in the region, with next generation sequencing companies like BGI Genomics and Oxford Nanopore Technologies driving innovation. India is also witnessing growth, focusing on affordable sequencing technologies and applications in agriculture and healthcare. The competitive landscape is characterized by a mix of local and international players, fostering a dynamic environment for advancements in NGS technologies. The region's potential is further enhanced by collaborations between governments and private sectors to boost research and development.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the Next Generation Sequencing Market, currently holding about 5% of the global market share. The growth is driven by increasing investments in healthcare and biotechnology, along with rising awareness of genomics applications. Countries like South Africa and the UAE are leading the way, focusing on enhancing their healthcare systems through advanced genomic technologies.

South Africa is at the forefront, with initiatives aimed at integrating genomics into public health strategies. The competitive landscape is still developing, with a mix of local and international players entering the market. The region's potential is significant, as governments are increasingly recognizing the importance of genomics in addressing healthcare challenges, paving the way for future growth in NGS technologies.

Key Players and Competitive Insights

The Next Generation Sequencing Market (NGS) Market is currently characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing applications in genomics, personalized medicine, and agricultural biotechnology. Major players such as Illumina (US), Thermo Fisher Scientific (US), and Oxford Nanopore Technologies (GB) are at the forefront, each adopting distinct strategies to enhance their market positioning.
 
Illumina (US) focuses on innovation through continuous product development, while Thermo Fisher Scientific (US) emphasizes strategic partnerships to expand its service offerings. Oxford Nanopore Technologies (GB) is leveraging its unique sequencing technology to penetrate new markets, particularly in real-time sequencing applications, thereby shaping a competitive environment that is increasingly reliant on technological differentiation.
 
In terms of business tactics, next generation sequencing companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The NGS market appears moderately fragmented, with a mix of established players and emerging next generation sequencing companies. This structure allows for a diverse range of offerings, but the collective influence of key players like BGI Genomics (CN) and Roche (CH) is significant, as they continue to innovate and expand their global reach.
 
In August 2025, Illumina (US) announced a strategic partnership with a leading pharmaceutical company to develop companion diagnostics, which is expected to enhance the integration of genomic data into clinical workflows. This collaboration not only strengthens Illumina's position in the personalized medicine space but also underscores the growing importance of partnerships in driving innovation and market penetration.
 
In September 2025, Thermo Fisher Scientific (US) launched a new NGS platform designed to streamline workflows and reduce turnaround times for genomic analysis. This introduction is pivotal as it aligns with the increasing demand for rapid and accurate sequencing solutions, positioning Thermo Fisher as a key player in meeting the evolving needs of researchers and clinicians.
 
In July 2025, Oxford Nanopore Technologies (GB) expanded its product line with the release of a portable sequencer aimed at field applications, particularly in environmental monitoring and infectious disease tracking. This move not only diversifies its product offerings but also highlights the trend towards accessibility and real-time data collection in genomics, potentially opening new revenue streams.
 
As of October 2025, the competitive trends in the NGS market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as next generation sequencing companies recognize the need to collaborate to enhance their technological capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, advanced technology, and reliable supply chains, reflecting the industry's shift towards more sophisticated and integrated solutions.

Key Companies in the Next Generation Sequencing Market include

Industry Developments

The Next Generation Sequencing Market has seen significant developments recently, particularly with notable advancements from key players. Oxford Nanopore Technologies continues to innovate with new sequencing technologies aimed at enhancing real-time data acquisition and analysis. 

Thermo Fisher Scientific has made strides in expanding its NGS portfolio by launching new instruments that facilitate high-throughput sequencing. In the merger and acquisition landscape, Illumina announced the acquisition of GRAIL in August 2021, focusing on early cancer detection through liquid biopsy technology, which is expected to strengthen its market position.

Meanwhile, in July 2023, Roche acquired GenMark Diagnostics to bolster its molecular diagnostics capabilities, further integrating its NGS offerings into the diagnostics market. The overall market is experiencing growth fueled by increased applications in personalized medicine, cancer research, and genetic testing, with the valuation of next generation sequencing companies like Pacific Biosciences and Qiagen also reflecting positive trends in this sector.

Additionally, regulatory support for genomic testing amid rising healthcare priorities is further driving investment and innovation across the Next Generation Sequencing Market, indicating a vibrant landscape for growth and collaboration among industry leaders in the coming years.

Future Outlook

Next Generation Sequencing Market Future Outlook

The Next Generation Sequencing Market size is projected to reach USD 48.81 Billion by 2035, growing at a CAGR of 11.54%, driven by technological advancements, increasing applications in genomics, and rising demand for personalized medicine.

New opportunities lie in:

  • <p>Development of portable sequencing devices for field applications. Expansion of cloud-based data analysis platforms for genomic data. Partnerships with pharmaceutical companies for drug development using NGS insights.</p>

By 2035, the Next Generation Sequencing Market is expected to be a pivotal component of genomic research and personalized healthcare.

Market Segmentation

Next Generation Sequencing Market End Use Outlook

  • Academic Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Hospitals and Clinics

Next Generation Sequencing Market Technology Outlook

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-Molecule Real-Time Sequencing
  • Nanopore Sequencing
  • Other Technologies

Next Generation Sequencing Market Application Outlook

  • Diagnostics
  • Research
  • Personalized Medicine
  • Agrigenomics

Next Generation Sequencing Market Product Type Outlook

  • Reagents
  • Instruments
  • Software
  • Services

Report Scope

MARKET SIZE 2024 14.68(USD Billion)
MARKET SIZE 2025 16.37(USD Billion)
MARKET SIZE 2035 48.81(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 11.54% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Illumina (US), Thermo Fisher Scientific (US), Pacific Biosciences (US), Oxford Nanopore Technologies (GB), BGI Genomics (CN), Qiagen (DE), Roche (CH), Agilent Technologies (US), Genomatix (DE)
Segments Covered Technology, Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Other Technologies, Product Type, Applications, End Use, Regional
Key Market Opportunities Advancements in personalized medicine drive demand for innovative applications in the Next Generation Sequencing Market.
Key Market Dynamics Technological advancements drive competitive forces, enhancing Next Generation Sequencing applications across diverse research and clinical settings.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Next Generation Sequencing Market by 2035?

<p>The Next Generation Sequencing Market is projected to reach a valuation of 48.81 USD Billion by 2035.</p>

What was the market valuation of the Next Generation Sequencing Market in 2024?

<p>In 2024, the market valuation of the Next Generation Sequencing Market was 14.68 USD Billion.</p>

What is the expected CAGR for the Next Generation Sequencing Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Next Generation Sequencing Market during the forecast period 2025 - 2035 is 11.54%.</p>

Which technology segment is anticipated to dominate the Next Generation Sequencing Market?

<p>The Sequencing by Synthesis technology segment is anticipated to dominate, with a projected valuation of 19.12 USD Billion by 2035.</p>

What are the key product types in the Next Generation Sequencing Market?

<p>Key product types include Reagents, Instruments, Software, and Services, with Instruments projected to reach 16.0 USD Billion by 2035.</p>

How does the application of personalized medicine impact the Next Generation Sequencing Market?

<p>The application of personalized medicine is expected to grow significantly, reaching a valuation of 12.0 USD Billion by 2035.</p>

Which end-use segment is likely to contribute the most to the Next Generation Sequencing Market?

<p>Hospitals and Clinics are likely to contribute the most, with a projected valuation of 16.31 USD Billion by 2035.</p>

Who are the leading companies in the Next Generation Sequencing Market?

<p>Leading companies in the market include Illumina, Thermo Fisher Scientific, and Pacific Biosciences, among others.</p>

What is the projected growth of the Ion Semiconductor Sequencing segment by 2035?

<p>The Ion Semiconductor Sequencing segment is projected to grow to 11.73 USD Billion by 2035.</p>

How does the market for Next Generation Sequencing compare across different end-use segments?

<p>The market for Next Generation Sequencing varies, with Pharmaceutical Companies expected to reach 14.0 USD Billion by 2035, indicating diverse growth across segments.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Technology (USD Billion)
    2. | | 4.1.1 Sequencing by Synthesis
    3. | | 4.1.2 Ion Semiconductor Sequencing
    4. | | 4.1.3 Single-Molecule Real-Time Sequencing
    5. | | 4.1.4 Nanopore Sequencing
    6. | | 4.1.5 Other Technologies
    7. | 4.2 Healthcare, BY Product Type (USD Billion)
    8. | | 4.2.1 Reagents
    9. | | 4.2.2 Instruments
    10. | | 4.2.3 Software
    11. | | 4.2.4 Services
    12. | 4.3 Healthcare, BY Application (USD Billion)
    13. | | 4.3.1 Diagnostics
    14. | | 4.3.2 Research
    15. | | 4.3.3 Personalized Medicine
    16. | | 4.3.4 Agrigenomics
    17. | 4.4 Healthcare, BY End Use (USD Billion)
    18. | | 4.4.1 Academic Institutes
    19. | | 4.4.2 Pharmaceutical Companies
    20. | | 4.4.3 Biotechnology Companies
    21. | | 4.4.4 Hospitals and Clinics
    22. | 4.5 Healthcare, BY Region (USD Billion)
    23. | | 4.5.1 North America
    24. | | | 4.5.1.1 US
    25. | | | 4.5.1.2 Canada
    26. | | 4.5.2 Europe
    27. | | | 4.5.2.1 Germany
    28. | | | 4.5.2.2 UK
    29. | | | 4.5.2.3 France
    30. | | | 4.5.2.4 Russia
    31. | | | 4.5.2.5 Italy
    32. | | | 4.5.2.6 Spain
    33. | | | 4.5.2.7 Rest of Europe
    34. | | 4.5.3 APAC
    35. | | | 4.5.3.1 China
    36. | | | 4.5.3.2 India
    37. | | | 4.5.3.3 Japan
    38. | | | 4.5.3.4 South Korea
    39. | | | 4.5.3.5 Malaysia
    40. | | | 4.5.3.6 Thailand
    41. | | | 4.5.3.7 Indonesia
    42. | | | 4.5.3.8 Rest of APAC
    43. | | 4.5.4 South America
    44. | | | 4.5.4.1 Brazil
    45. | | | 4.5.4.2 Mexico
    46. | | | 4.5.4.3 Argentina
    47. | | | 4.5.4.4 Rest of South America
    48. | | 4.5.5 MEA
    49. | | | 4.5.5.1 GCC Countries
    50. | | | 4.5.5.2 South Africa
    51. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Illumina (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Thermo Fisher Scientific (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Pacific Biosciences (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Oxford Nanopore Technologies (GB)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 BGI Genomics (CN)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Qiagen (DE)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Roche (CH)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Agilent Technologies (US)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Genomatix (DE)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TECHNOLOGY
    4. | 6.4 US MARKET ANALYSIS BY PRODUCT TYPE
    5. | 6.5 US MARKET ANALYSIS BY APPLICATION
    6. | 6.6 US MARKET ANALYSIS BY END USE
    7. | 6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY
    8. | 6.8 CANADA MARKET ANALYSIS BY PRODUCT TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY APPLICATION
    10. | 6.10 CANADA MARKET ANALYSIS BY END USE
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    13. | 6.13 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
    14. | 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY END USE
    16. | 6.16 UK MARKET ANALYSIS BY TECHNOLOGY
    17. | 6.17 UK MARKET ANALYSIS BY PRODUCT TYPE
    18. | 6.18 UK MARKET ANALYSIS BY APPLICATION
    19. | 6.19 UK MARKET ANALYSIS BY END USE
    20. | 6.20 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    21. | 6.21 FRANCE MARKET ANALYSIS BY PRODUCT TYPE
    22. | 6.22 FRANCE MARKET ANALYSIS BY APPLICATION
    23. | 6.23 FRANCE MARKET ANALYSIS BY END USE
    24. | 6.24 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    25. | 6.25 RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION
    27. | 6.27 RUSSIA MARKET ANALYSIS BY END USE
    28. | 6.28 ITALY MARKET ANALYSIS BY TECHNOLOGY
    29. | 6.29 ITALY MARKET ANALYSIS BY PRODUCT TYPE
    30. | 6.30 ITALY MARKET ANALYSIS BY APPLICATION
    31. | 6.31 ITALY MARKET ANALYSIS BY END USE
    32. | 6.32 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    33. | 6.33 SPAIN MARKET ANALYSIS BY PRODUCT TYPE
    34. | 6.34 SPAIN MARKET ANALYSIS BY APPLICATION
    35. | 6.35 SPAIN MARKET ANALYSIS BY END USE
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY TECHNOLOGY
    42. | 6.42 CHINA MARKET ANALYSIS BY PRODUCT TYPE
    43. | 6.43 CHINA MARKET ANALYSIS BY APPLICATION
    44. | 6.44 CHINA MARKET ANALYSIS BY END USE
    45. | 6.45 INDIA MARKET ANALYSIS BY TECHNOLOGY
    46. | 6.46 INDIA MARKET ANALYSIS BY PRODUCT TYPE
    47. | 6.47 INDIA MARKET ANALYSIS BY APPLICATION
    48. | 6.48 INDIA MARKET ANALYSIS BY END USE
    49. | 6.49 JAPAN MARKET ANALYSIS BY TECHNOLOGY
    50. | 6.50 JAPAN MARKET ANALYSIS BY PRODUCT TYPE
    51. | 6.51 JAPAN MARKET ANALYSIS BY APPLICATION
    52. | 6.52 JAPAN MARKET ANALYSIS BY END USE
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY END USE
    61. | 6.61 THAILAND MARKET ANALYSIS BY TECHNOLOGY
    62. | 6.62 THAILAND MARKET ANALYSIS BY PRODUCT TYPE
    63. | 6.63 THAILAND MARKET ANALYSIS BY APPLICATION
    64. | 6.64 THAILAND MARKET ANALYSIS BY END USE
    65. | 6.65 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    66. | 6.66 INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION
    68. | 6.68 INDONESIA MARKET ANALYSIS BY END USE
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY END USE
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    75. | 6.75 BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION
    77. | 6.77 BRAZIL MARKET ANALYSIS BY END USE
    78. | 6.78 MEXICO MARKET ANALYSIS BY TECHNOLOGY
    79. | 6.79 MEXICO MARKET ANALYSIS BY PRODUCT TYPE
    80. | 6.80 MEXICO MARKET ANALYSIS BY APPLICATION
    81. | 6.81 MEXICO MARKET ANALYSIS BY END USE
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY END USE
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY END USE
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY END USE, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY END USE, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY END USE, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY END USE, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY END USE, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY END USE, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY END USE, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY END USE, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY END USE, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY END USE, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY END USE, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY END USE, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY END USE, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY END USE, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY END USE, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY END USE, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY END USE, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY END USE, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY END USE, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY END USE, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY END USE, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY END USE, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY END USE, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY END USE, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY END USE, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY END USE, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY END USE, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY END USE, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY END USE, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Technology (USD Billion, 2025-2035)

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-Molecule Real-Time Sequencing
  • Nanopore Sequencing
  • Other Technologies

Healthcare By Product Type (USD Billion, 2025-2035)

  • Reagents
  • Instruments
  • Software
  • Services

Healthcare By Application (USD Billion, 2025-2035)

  • Diagnostics
  • Research
  • Personalized Medicine
  • Agrigenomics

Healthcare By End Use (USD Billion, 2025-2035)

  • Academic Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Hospitals and Clinics
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓